Stockhouse.com uses cookies on this site. By continuing to use our service, you agree to our use of cookies. Cookies are used to offer you a better browsing experience and to analyze our traffic. We also use them to share usage information with our partners. See full details.
I Agree
×
Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Privacy Policy | Disclaimer

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Privacy Policy | Disclaimer
Please Try Again {{ error }}

Send my password

Return to Login
SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Quote  |  Bullboard  |  News  |  Opinion  |  Profile  |  Peers  |  Filings  |  Financials  |  Options  |  Price History  |  Ratios  |  Ownership  |  Insiders  |  Valuation

Vaxil Bio Ltd V.VXL

Alternate Symbol(s):  VXLLF

Healthcare Biotechnology
Vaxil Bio Ltd. is a Canada-based biotechnology company. The Company is focused on a drug discovery and development platform based on Signal Peptides (SPs) which the Company deploys to fight infectious diseases and cancer. The Company’s most advanced product, ImMucin, a MUC1 SP-derived vaccine, completed a Phase I/II clinical trial in multiple myeloma. The Company also has a SP-based COVID-19 vaccine candidate and a SP-based tuberculosis vaccine / treatment candidate. In addition, The Company has mAb candidates for the treatment of oncology and infectious diseases to be used alone, and in combination with other treatments. It has also initiated a pre-clinical program for a drug delivery polymer that targets high affinity E-selectin (P-Esbp), which the Company licensed for development and commercialization from BGN Technologies. It exploits the properties of SP domains on crucial proteins to develop targeted therapies against cancer targets and infectious disease pathogens.


TSXV:VXL - Post by User

Vaxil Bio Ltd > Moderna Announces it has Shipped Variant-Specific Vaccine Ca
<< Previous
 Bullboard Posts
Next >>
User Avatar Image
(120)
•••
Comment by CamaroZL1on Feb 24, 2021 6:33pm
71 Views
Post# 32653890

RE:RE:RE:RE:Moderna Announces it has Shipped Variant-Specific Vaccine Ca

RE:RE:RE:RE:Moderna Announces it has Shipped Variant-Specific Vaccine Ca
bligicka wrote: A immune response was obtained....yes but no protective antibodies were detected ......without any protection we really don't have a vaccine .....hence the .165 share price !!! 

I don't think they will be able to tweek something they aren't even detecting at all ......sucks to be a Vaxil bag holder ....we may see a update on imMucin but the problem is everyone is here for the covid19 potential 








silentrunning wrote: A "response" was obtained.....what we don't know yet is what was it? We have an outstanding technology....just needs tweaking now.




I think the covid people were wiped out. They were here. There is no covid vaccine agreed. Single peptide technology is what they have. Monthly and weekly trends OTC are still up for some reason.
<< Previous
 Bullboard Posts
Next >>
Dealroom for high-potential pre-IPO opportunities